Business
Publication of a Prospectus
Publication of a Prospectus.
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 8500Z Circassia Pharmaceuticals Plc 17 March 2017 \n\nCircassia Pharmaceuticals plc\n17 March 2017\n \nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION\n \nThis announcement is not an advertisement and not an offer of securities for sale in any jurisdiction, including in the United States, Canada, Australia, Japan and South Africa. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the \"Securities Act\"). Circassia Pharmaceuticals plc does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.\n \nNeither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Any decision in respect of the Transaction should be made solely on the basis of the information that is contained in the combined prospectus and circular.\n \n \nCircassia Pharmaceuticals plc\n \nPUBLICATION AND POSTING OF PROSPECTUS AND NOTICE OF GENERAL MEETING\n \nFurther to the announcement of 17 March 2017 by Circassia Pharmaceuticals plc (\"Circassia\" or the \"Company\"), that it has reached agreement to enter into a collaboration with and secure certain U.S. commercial rights from AstraZeneca in respect of Tudorza® and Duaklir®* for consideration of up to U.S.$230 million (including U.S.$50 million in Ordinary Shares (the \"Consideration Shares\") on completion) plus future royalties based on Duaklir® sales (the \"Transaction\"), the Company today announces that a combined prospectus and circular dated 17 March 2017 (the \"Prospectus\") has been approved by the UK Listing Authority and submitted to the National Storage Mechanism. It will shortly be available for inspection at www.morningstar.co.uk/uk/NSM.\n \nThe Prospectus will also shortly be available to view or download on the 'Investor Relations' section ...